Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025)

Neurogene (NGNE) posted Asset Writedowns and Impairment of $120000.0 for Q4 2025, up 31.87% on a QoQ basis from $91000.0 in Q1 2024.

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends

Neurogene's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $120000.0 for Q4 2025.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $120000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $120000.0 (up 31.87% YoY) and the FY2025 annual result came in at $120000.0, up 31.87% from the prior year.
Asset Writedowns and Impairment was $120000.0 for Q4 2025 at Neurogene, up from $91000.0 in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $120000.0 in Q4 2025 and bottomed at $91000.0 in Q1 2024.
A 3-year average of $103666.7 and a median of $100000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Neurogene	776.69 Mn	776.69 Mn	-

Download Data